Medicare, GLP-1s and the $50 month
CMS is running a time-limited programme giving eligible Part D members certain GLP-1s for $50 a month. If you are on Medicare, read this before paying cash for anything.
Updated 2026-09-18
The single biggest price move in this market did not come from a telehealth company. It came from CMS, and it takes effect on 1 July 2026.
That is less than every cash-pay programme we track. The cheapest compounded tirzepatide on this site is Trimi at $125 a month and the cheapest semaglutide is Ozari Health at $86. A $50 copay undercuts both, for an FDA-approved product rather than a compounded one.
What it does to the board
A $50 copay sits below every listing we track. For the cohort that qualifies, it resets the entire board — the cheapest cash programme becomes the second-cheapest option, and the dearest becomes indefensible. The desk would rather print that than pretend the board is the whole market.
What was actually announced
CMS will give eligible Medicare beneficiaries access to certain GLP-1 medications for $50 for a monthly supply, beginning 1 July 2026 and running through 31 December 2027.
- It is a time-limited demonstration, not a permanent benefit — it is currently scheduled to end on 31 December 2027.
- You must be enrolled in a Medicare Part D prescription drug plan to be eligible.
- It covers certain GLP-1 medications; CMS has said it will publish more detail for beneficiaries as the programme begins.
- Separately, manufacturers agreed to price the injectable products at around $245 per month for Medicare, with beneficiary copays capped at $50.
- Whether a GLP-1 is appropriate for you is a decision for your doctor — eligibility for the programme is not the same as a clinical recommendation.
Announced in the CMS press release, 6 May 2026. CMS has published further detail at cms.gov, and says it will release more for beneficiaries as the programme starts.
Read this bit. The part people will miss. It is a demonstration with an end date — currently 31 December 2027. It is not a permanent Medicare benefit, and nobody should assume the $50 price continues past that without checking.
How it compares with paying cash
| Route | Monthly | FDA-approved? |
|---|---|---|
| Medicare GLP-1 Bridge (from 1 July 2026) | $50 | Yes |
| Cheapest compounded semaglutide (Ozari Health) | $86 | No — compounded |
| Cheapest compounded tirzepatide (Trimi) | $125 | No — compounded |
| Wegovy pill, self-pay | $149+ | Yes |
| Foundayo (orforglipron), self-pay | $149+ | Yes |
Separately, manufacturers agreed to price the injectable products at around $245 a month for Medicare, with beneficiary copays capped at $50. The two things together mean the cash-pay compounded market is no longer the obvious cheap option it was in 2024.
If you are not on Medicare
This programme will not help you, but the approved oral products might — both now start at $149 a month. We go through them in the FDA-approved pills. If you are still paying cash for a compounded injection, compare it against those before renewing.
Nothing here is medical advice, and we are not affiliated with CMS or Medicare. Check your own eligibility with Medicare directly and your treatment with your doctor.
More from the desk
- The approved pills changed the maths
Two oral GLP-1s were approved either side of the new year, both starting at $149 a month. That undercuts a large part of the compounded market.
- Six fee traps
Every advertised-to-billed gap on our board comes from one of these six structures. Learn them and you can read any of these sites in ninety seconds.
- The compounding rules
Cheap GLP-1s exist because of compounding. The FDA moved against it again in April. What that means for the board.
- GLP-1s after 50
These drugs work at any age. The risks are not identical at every age, and the muscle and bone question deserves more attention than it usually gets.
- Cheapest right now
Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.
Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure